| __timestamp | Opthea Limited | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2652041 | 381287000 |
| Thursday, January 1, 2015 | 2361587 | 452612000 |
| Friday, January 1, 2016 | 4472869 | 316800000 |
| Sunday, January 1, 2017 | 5030957 | 330100000 |
| Monday, January 1, 2018 | 4988941 | 265800000 |
| Tuesday, January 1, 2019 | 5196412 | 336200000 |
| Wednesday, January 1, 2020 | 6652774 | 423900000 |
| Friday, January 1, 2021 | 18418247 | 467000000 |
| Saturday, January 1, 2022 | 24827066 | 487000000 |
| Sunday, January 1, 2023 | 41896408 | 477100000 |
| Monday, January 1, 2024 | 15488619 |
Data in motion
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. United Therapeutics Corporation and Opthea Limited, two prominent companies, exhibit distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, United Therapeutics consistently allocated a significant portion of its budget to SG&A, peaking at nearly 480% more than Opthea's highest expenditure in 2022. This strategic investment underscores their commitment to robust operational management and market presence. In contrast, Opthea's SG&A spending surged by over 1,500% from 2014 to 2023, reflecting a strategic pivot towards aggressive growth and expansion.
These contrasting approaches highlight the diverse strategies within the industry, offering valuable insights into how companies prioritize their resources to achieve competitive advantage.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Verona Pharma plc
United Therapeutics Corporation vs Ultragenyx Pharmaceutical Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Alkermes plc
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Geron Corporation
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Opthea Limited Trends and Insights
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Opthea Limited
Opthea Limited or Xenon Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Opthea Limited and Merus N.V.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Opthea Limited vs MorphoSys AG Trends and Insights
Cost Management Insights: SG&A Expenses for Opthea Limited and Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Opthea Limited vs Geron Corporation